Nanthealth LLC (NYSE:NH)’s share price traded up 7.8% during trading on Wednesday . The company traded as high as $12.74 and last traded at $12.64, with a volume of 73,044 shares traded. The stock had previously closed at $11.73.

A number of equities analysts have commented on the company. FBR & Co reaffirmed a “buy” rating on shares of Nanthealth in a research note on Wednesday, August 10th. Jefferies Group started coverage on Nanthealth in a research report on Monday, June 27th. They issued a “buy” rating on the stock. Canaccord Genuity started coverage on Nanthealth in a research report on Monday, June 27th. They issued a “buy” rating and a $17.00 price objective on the stock. First Analysis started coverage on Nanthealth in a research report on Monday, June 27th. They issued an “overweight” rating and a $18.00 price objective on the stock. Finally, Cowen and Company started coverage on Nanthealth in a research report on Monday, June 27th. They issued an “outperform” rating and a $19.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, Nanthealth presently has an average rating of “Buy” and a consensus target price of $18.00.

The firm’s market cap is $1.49 billion. The firm has a 50 day moving average price of $11.56 and a 200 day moving average price of $12.37.

Nanthealth (NYSE:NH) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.26. The firm had revenue of $31.50 million for the quarter, compared to the consensus estimate of $23.55 million. Nanthealth’s revenue was up 166.9% compared to the same quarter last year. Equities research analysts anticipate that Nanthealth LLC will post ($0.59) earnings per share for the current year.

In related news, major shareholder Healthcare Solution Allscripts acquired 714,286 shares of the firm’s stock in a transaction on Tuesday, June 7th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $10,000,004.00. Following the completion of the transaction, the insider now directly owns 15,000,000 shares in the company, valued at approximately $210,000,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Patrick Soon-Shiong acquired 357,143 shares of the firm’s stock in a transaction on Tuesday, June 7th. The shares were bought at an average price of $14.00 per share, for a total transaction of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.